Highly-reproducible quantitative proteomics analysis of pancreatic cancer cells reveals proteome-level effects of a novel combination drug therapy that induces cancer cell death via metabolic remodeling and activation of the extrinsic apoptosis pathway
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion Lumos
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Epithelial Cell, Cell Culture
DISEASE(S): Pancreatic Ductal Adenocarcinoma
SUBMITTER: 
Sailee Rasam
LAB HEAD: Dr. Jun Qu
PROVIDER: PXD044149 | Pride | 2024-11-19
REPOSITORIES: Pride
Dataset's files
Items per page: 5 1 - 5 of 127 |
Similar Datasets
Project description:A Gemcitabine resistant cell line was generated and treated with Gemcitabine for further analysis
2022-09-15 | PXD030859 | Pride
Project description:Pancreatic cancer cells (MIA PaCa-2) were treated with Gemcitabine and overall protein changes were studied
2022-09-15 | PXD030861 | Pride
Project description:Despite decades of effort, pancreatic adenocarcinoma (PDAC) remains an intractable clinical challenge. An insufficient understanding of mechanisms underlying tumor cell responses to chemotherapy contributes significantly to the lack of effective treatment regimens. Here, paclitaxel, a first-line chemotherapeutic agent, was observed to interact synergistically with birinapant, a Second Mitochondrial-derived Activator of Caspases mimetic. Therefore, we investigated molecular-level drug interaction mechanisms using comprehensive, reproducible, and well-controlled ion-current-based MS1 quantification (IonStar). In a set of 40 biological samples, we compared temporal proteomic responses of PDAC cells treated with birinapant and paclitaxel, alone and combined. Using stringent criteria (e.g. strict false-discovery-rate FDR control, 2 peptides/protein), we quantified 4069 unique proteins confidently (99.8% without any missing data), and 541 proteins were significantly altered in the three treatment groups with a FDR of <1%. Interestingly, most of these proteins were altered only by combined birinapant/paclitaxel, and these predominantly represented three biological processes: mitochondrial function, cell growth and apoptosis, and cell cycle arrest. Proteins responsible for activation of oxidative phosphorylation, fatty acid β-oxidation, and inactivation of aerobic glycolysis were altered largely by combined birinapant/paclitaxel compared to single drugs, suggesting that the Warburg effect, which is employed by PDAC cells for survival and proliferation, was alleviated by the combination treatment. Metabolic profiling confirmed substantially greater suppression of the Warburg effect by the combined agents compared to either drug alone. Western blot analysis confirmed changes in apoptosis/survival signaling pathways, such as inhibition of PI3K/AKT, JAK/STAT, and MAPK/ERK signal transduction, as well as induction of G2/M arrest, and the drug combination induced much more apoptosis than did single agents. Overall, this in-depth, large-scale proteomics study provided novel insights into molecular mechanisms underlying synergy of combined birinapant/paclitaxel, and describes a proteomics/informatics pipeline that can be applied broadly to the development of cancer drug combination regimens.
2018-01-29 | PXD007890 | Pride
Project description:Quantitative proteomics in large cohorts is highly valuable for biomedical/pharmaceutical investigations but often suffers from suboptimal reliability, accuracy, and reproducibility. Here we describe a new ultra-high-resolution (UHR) IonStar method achieving precise/reproducible protein measurement in large-cohorts while eliminating accuracy-related problems such as ratio compression, by taking advantage of the exceptional selectivity of UHR-MS1 detection (240k_FWHM). Using mixed-proteome sets reflecting large-cohort analysis using technical or biological replicates (N=56), we comprehensively compared the quantitative performances of UHR-IonStar with a state-of-the-art SWATH-MS method. The SWATH-MS employs a cutting-edge TripleTOF and a SpectronautTM package and was meticulously optimized to maximize sensitivity, reproducibility and proteome-coverage, by developing a highly extensive, customized spectral-library, reproducible/robust capillary-LC separation and narrow, variable-window acquisition. Comparing quantitative performances of the two distinct methods (i.e. MS1-vs.MS2-based) affords interesting and valuable observations. While the performances for higher-abundance proteins (i.e. higher 75% proteins in abundance) are quite similar by the two methods, UHR-IonStar showed markedly better quantitative accuracy, precision and reproducibility (e.g. R2>0.9 by UHR-IonStar vs. R2<0.4 by SWATH-MS) for proteins of lower 25% in abundance, and much improved sensitivity/selectivity for discovering significantly-altered proteins, especially these with changes ≤2.5 folds. Furthermore, UHR-IonStar showed more accurate protein quantification in single analysis of each individual sample in a large set, which is an inadequately-investigated albeit highly critical parameter for large-cohort analysis. Finally, we compared the two methods in measuring time courses of altered proteins in cancer cells (N=36) treated by paclitaxel, where dysregulated biological processes have been well-established. UHR-IonStar discovered more altered-proteins in biological processes and pathways that are known to be induced by paclitaxel, with substantially better significance scores. Additionally, UHR-IonStar showed markedly superior ability in accurately depicting the time courses of tubulin-α/β isoforms which are well-known to be consistently induced by paclitaxel. In summary, UHR-IonStar represents a reliable, robust and cost-effective solution for large-cohort proteomics quantification with excellent accuracy and precision.
2021-06-24 | PXD017865 | Pride
Project description:Quantitative proteomics in large cohorts is highly valuable for biomedical/pharmaceutical investigations but often suffers from suboptimal reliability, accuracy, and reproducibility. Here we describe a new ultra-high-resolution (UHR) IonStar method achieving precise/reproducible protein measurement in large-cohorts while eliminating accuracy-related problems such as ratio compression, by taking advantage of the exceptional selectivity of UHR-MS1 detection (240k_FWHM). Using mixed-proteome sets reflecting large-cohort analysis using technical or biological replicates (N=56), we comprehensively compared the quantitative performances of UHR-IonStar with a state-of-the-art SWATH-MS method. The SWATH-MS employs a cutting-edge TripleTOF and a SpectronautTM package and was meticulously optimized to maximize sensitivity, reproducibility and proteome-coverage, by developing a highly extensive, customized spectral-library, reproducible/robust capillary-LC separation and narrow, variable-window acquisition. Comparing quantitative performances of the two distinct methods (i.e. MS1-vs.MS2-based) affords interesting and valuable observations. While the performances for higher-abundance proteins (i.e. higher 75% proteins in abundance) are quite similar by the two methods, UHR-IonStar showed markedly better quantitative accuracy, precision and reproducibility (e.g. R2>0.9 by UHR-IonStar vs. R2<0.4 by SWATH-MS) for proteins of lower 25% in abundance, and much improved sensitivity/selectivity for discovering significantly-altered proteins, especially these with changes ≤2.5 folds. Furthermore, UHR-IonStar showed more accurate protein quantification in single analysis of each individual sample in a large set, which is an inadequately-investigated albeit highly critical parameter for large-cohort analysis. Finally, we compared the two methods in measuring time courses of altered proteins in cancer cells (N=36) treated by paclitaxel, where dysregulated biological processes have been well-established. UHR-IonStar discovered more altered-proteins in biological processes and pathways that are known to be induced by paclitaxel, with substantially better significance scores. Additionally, UHR-IonStar showed markedly superior ability in accurately depicting the time courses of tubulin-α/β isoforms which are well-known to be consistently induced by paclitaxel. In summary, UHR-IonStar represents a reliable, robust and cost-effective solution for large-cohort proteomics quantification with excellent accuracy and precision.
2021-06-24 | PXD017915 | Pride
Project description:Quantitative proteomics in large cohorts is highly valuable for biomedical/pharmaceutical investigations but often suffers from suboptimal reliability, accuracy, and reproducibility. Here we describe a new ultra-high-resolution (UHR) IonStar method achieving precise/reproducible protein measurement in large-cohorts while eliminating accuracy-related problems such as ratio compression, by taking advantage of the exceptional selectivity of UHR-MS1 detection (240k_FWHM). Using mixed-proteome sets reflecting large-cohort analysis using technical or biological replicates (N=56), we comprehensively compared the quantitative performances of UHR-IonStar with a state-of-the-art SWATH-MS method. The SWATH-MS employs a cutting-edge TripleTOF and a SpectronautTM package and was meticulously optimized to maximize sensitivity, reproducibility and proteome-coverage, by developing a highly extensive, customized spectral-library, reproducible/robust capillary-LC separation and narrow, variable-window acquisition. Comparing quantitative performances of the two distinct methods (i.e. MS1-vs.MS2-based) affords interesting and valuable observations. While the performances for higher-abundance proteins (i.e. higher 75% proteins in abundance) are quite similar by the two methods, UHR-IonStar showed markedly better quantitative accuracy, precision and reproducibility (e.g. R2>0.9 by UHR-IonStar vs. R2<0.4 by SWATH-MS) for proteins of lower 25% in abundance, and much improved sensitivity/selectivity for discovering significantly-altered proteins, especially these with changes ≤2.5 folds. Furthermore, UHR-IonStar showed more accurate protein quantification in single analysis of each individual sample in a large set, which is an inadequately-investigated albeit highly critical parameter for large-cohort analysis. Finally, we compared the two methods in measuring time courses of altered proteins in cancer cells (N=36) treated by paclitaxel, where dysregulated biological processes have been well-established. UHR-IonStar discovered more altered-proteins in biological processes and pathways that are known to be induced by paclitaxel, with substantially better significance scores. Additionally, UHR-IonStar showed markedly superior ability in accurately depicting the time courses of tubulin-α/β isoforms which are well-known to be consistently induced by paclitaxel. In summary, UHR-IonStar represents a reliable, robust and cost-effective solution for large-cohort proteomics quantification with excellent accuracy and precision.
2021-06-24 | PXD017812 | Pride
Project description:Osteoclasts (OCs) are bone-resorbing cells differentiated from macrophage/monocyte precursors in response to M-CSF and RANKL. In vitro models are principally based on primary bone marrow macrophages, but RAW 264.7 cells are frequently used because they are widely available, easy to culture, and more amenable to genetic manipulation than primary cells. Increasing evidence, however, has shown that the vastly different origins of these two cell types may have important effects on cell behavior. In particular, M-CSF is prerequisite for the differentiation of BMMs, by promoting survival and proliferation and priming the cells for RANKL induction. RAW 264.7 cells readily form OCs in the presence of RANKL, but M-CSF is not required. Based on these key differences, we sought to understand their functional implications and how it might affect osteoclast differentiation and related signaling pathways. Using a robust and high-throughput proteomics strategy, we quantified the global protein changes in OCs derived from bone marrow macrophages and RAW 264.7 cells at 1, 3, and 5 days of differentiation. Correlation analysis of the proteomes demonstrated low concordance between the two cell types (R2 ≈ 0.13). Bioinformatics analysis indicate that RANKL-dependent signaling was intact in RAW 264.7 cells, but biological processes known to be dependent on M-CSF were significantly different; including cell cycle control, cytoskeletal organization, and apoptosis. RAW 264.7 cells exhibited constitutive activation of Erk and Akt that was dependent on the activity of Abelson tyrosine kinase, and the timing of Erk and Akt activation was significantly different between BMMs and RAW 264.7 cells. Our findings provide the first evidence for major differences between BMMs and RAW 264.7 cells, indicating that careful consideration is needed when using the RAW 264.7 cell line when studying M-CSF-dependent signaling and functions.
2018-11-27 | PXD009610 | Pride
Project description:Trypanosoma brucei occupies distinct niches throughout its life cycle, both within the vertebrate host (fat tissue, bloodstream, central nervous system) and within the insect host, the tsetse fly (taken up with a bloodmeal and passing through the midgut, and migrating to the salivary glands). The immunological and biochemical complexity and variability of each of these environments require a reshaping of the protein landscape of the parasite both to evade surveillance and face changing metabolic demands. Whereas most well-studied organisms rely on transcriptional control as the main regulator of gene expression, post-transcriptional control mechanisms are particularly important in T. brucei, and these are often mediated by RNA-binding proteins. DRBD18 is a T. brucei RNA binding protein that interacts with ribosomal proteins and translation factors. Here, we tested a role for DRBD18 in translational control. We show that DRBD18 depletion by RNA interference leads to altered polysomal profiles with a specific depletion of heavy polysomes. RiboSeq analysis reveals that 101 transcripts change in translational efficiency (TE) upon DRBD18 depletion: 41 of them exhibit decreased TE and 60 increased TE. A further 66 transcripts are buffered, i.e. changes in transcript abundance are compensated by changes in TE such that the total translational output is expected not to change. Proteomic analysis validates much of these data. In DRBD18 depleted cells, a cohort of transcripts that code for procyclic form specific proteins are translationally repressed while, conversely, transcripts that code for bloodstream form specific proteins are translationally enhanced. These data suggest that DRBD18 contributes to the maintenance of the procyclic state through both positive and negative translational control of specific mRNAs.
2024-01-26 | PXD039064 | Pride
Project description:Age-related macular degeneration (AMD) is the leading cause of blindness in seniors, with no effective treatment options available for most patients. AMD is characterized by the death of retinal pigment epithelium (RPE) and photoreceptors, resulting in central vision loss causing tremendous difficulties in performing daily tasks requiring visualization of fine details visualization. Dysfunction of RPE mitochondria is a critical early event involved in AMD pathogenesis, and we previously reported that maintaining normal mitochondrial functions in RPE could be a viable option for AMD treatment. We hypothesize that dysregulation of RPE mitochondrial proteome is highly relevant to the loss of RPE mitochondrial function during the transition from healthy aging to early AMD. The hypothesis was examined by quantitative proteomics using UHR-IonStar.
2022-07-13 | PXD033413 | Pride
Project description:Quantitative protein mapping on whole-tissue levels provides important insights into the spatially-organized regulatory processes/networks related to diseases and therapy, but remains a tremendous challenge. We describe a micro-scaffold assisted spatial proteomics(MASP) method, based on precise tissue spatial-compartmentalization using a 3D-printed micro-scaffold, capable of mapping thousands of proteins across a whole-tissue slice with excellent quantitative quality. The mapping accuracy was validated and applied in mapping >5,000 cerebral proteins in mouse brain. Under stringent cutoffs, 5019 unique proteins were mapped(N=208 micro-specimens) and 4577 proteins were mapped in all regions.
2023-03-11 | PXD037041 | Pride